DK1230236T3 - Forbindelse med væksthormonfrigörende egenskaber - Google Patents

Forbindelse med væksthormonfrigörende egenskaber

Info

Publication number
DK1230236T3
DK1230236T3 DK00974349T DK00974349T DK1230236T3 DK 1230236 T3 DK1230236 T3 DK 1230236T3 DK 00974349 T DK00974349 T DK 00974349T DK 00974349 T DK00974349 T DK 00974349T DK 1230236 T3 DK1230236 T3 DK 1230236T3
Authority
DK
Denmark
Prior art keywords
growth hormone
compound
hormone releasing
releasing properties
trimethylhydrazinocarbonyl
Prior art date
Application number
DK00974349T
Other languages
Danish (da)
English (en)
Inventor
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK1230236T3 publication Critical patent/DK1230236T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK00974349T 1999-11-10 2000-11-10 Forbindelse med væksthormonfrigörende egenskaber DK1230236T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901618 1999-11-10
US16710199P 1999-11-23 1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en) 1999-11-10 2000-11-10 Compound with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
DK1230236T3 true DK1230236T3 (da) 2005-02-21

Family

ID=26065963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00974349T DK1230236T3 (da) 1999-11-10 2000-11-10 Forbindelse med væksthormonfrigörende egenskaber

Country Status (23)

Country Link
US (1) US6576648B2 (ja)
EP (1) EP1230236B1 (ja)
JP (2) JP2003527338A (ja)
KR (1) KR100907637B1 (ja)
CN (1) CN1198818C (ja)
AT (1) ATE280168T1 (ja)
AU (1) AU782260B2 (ja)
BR (1) BR0015407A (ja)
CA (1) CA2387095C (ja)
CZ (1) CZ301078B6 (ja)
DE (1) DE60015173T2 (ja)
DK (1) DK1230236T3 (ja)
ES (1) ES2231279T3 (ja)
HU (1) HU229445B1 (ja)
IL (1) IL149049A0 (ja)
MX (1) MXPA02004656A (ja)
NO (1) NO323910B1 (ja)
PL (1) PL199989B1 (ja)
PT (1) PT1230236E (ja)
RU (1) RU2272034C2 (ja)
UA (1) UA73530C2 (ja)
WO (1) WO2001034593A1 (ja)
ZA (1) ZA200202757B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565324A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US20130281701A1 (en) 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
AU2005272074B2 (en) * 2004-06-29 2011-11-24 Albany Molecular Research, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR101324340B1 (ko) * 2004-06-29 2013-10-31 헬신 세라퓨틱스 (유.에스.) 인크. (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US7884107B2 (en) * 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US8664267B2 (en) * 2007-04-12 2014-03-04 Academic Pharmaceuticals Incorporated Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
PT2241564E (pt) 2008-02-08 2014-06-12 Zeria Pharm Co Ltd Derivado de 3,8-diaminotetra-hidroquinolina
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
KR20200108494A (ko) 2012-10-24 2020-09-18 다이이찌 산쿄 가부시키가이샤 근위축성 측삭 경화증 치료제
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
CN106187865A (zh) * 2016-07-08 2016-12-07 武汉工程大学 (r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108129357B (zh) * 2016-12-01 2021-12-21 上海医药工业研究院 阿拉莫林中间体的制备方法
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
CN114630655A (zh) * 2019-08-30 2022-06-14 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68912775T2 (de) 1988-05-11 1994-06-30 Polygen Holding Corp Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
SK56296A3 (en) * 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
EP0730578A4 (en) 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
DE69921611T2 (de) * 1998-01-16 2005-11-03 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
SI1077941T1 (sl) * 1998-05-11 2010-01-29 Novo Nordisk As Spojine, ki imajo lastnost sproščanja rastnega hormona
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake

Also Published As

Publication number Publication date
NO20022200D0 (no) 2002-05-08
CA2387095A1 (en) 2001-05-17
HU229445B1 (en) 2013-12-30
UA73530C2 (uk) 2005-08-15
NO20022200L (no) 2002-05-08
HUP0203844A2 (hu) 2003-03-28
HUP0203844A3 (en) 2004-07-28
BR0015407A (pt) 2002-07-02
CA2387095C (en) 2011-01-11
ES2231279T3 (es) 2005-05-16
AU1269401A (en) 2001-06-06
IL149049A0 (en) 2002-11-10
MXPA02004656A (es) 2002-09-02
CN1198818C (zh) 2005-04-27
US20010041720A1 (en) 2001-11-15
EP1230236B1 (en) 2004-10-20
AU782260B2 (en) 2005-07-14
PL356993A1 (en) 2004-07-12
JP5053960B2 (ja) 2012-10-24
KR20020059694A (ko) 2002-07-13
DE60015173D1 (de) 2004-11-25
JP2003527338A (ja) 2003-09-16
US6576648B2 (en) 2003-06-10
DE60015173T2 (de) 2005-12-08
RU2272034C2 (ru) 2006-03-20
KR100907637B1 (ko) 2009-07-14
EP1230236A1 (en) 2002-08-14
ATE280168T1 (de) 2004-11-15
CZ20021587A3 (cs) 2002-09-11
WO2001034593A1 (en) 2001-05-17
PL199989B1 (pl) 2008-11-28
CN1420878A (zh) 2003-05-28
PT1230236E (pt) 2005-03-31
CZ301078B6 (cs) 2009-10-29
NO323910B1 (no) 2007-07-16
JP2009062369A (ja) 2009-03-26
ZA200202757B (en) 2003-02-26

Similar Documents

Publication Publication Date Title
DK1230236T3 (da) Forbindelse med væksthormonfrigörende egenskaber
JO2371B1 (en) 4-phenyl-pyridine derivatives
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ATE248837T1 (de) Chinuclidin-acrylamide
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
SE9903997D0 (sv) New compounds
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
SE0102055D0 (sv) New Compounds
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists